GILD Reports Positive Results From Late-Stage Liver Disease Study
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Yahoo Finance
Updated Jun 2, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.
Recent share performance and business scale Gilead Sciences (GILD) has seen its stock decline 2.7% over the past day and 4.6% over the past week, adding to a f…
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead has touted the potential of its liver disease drug in patients with high ALP levels, potentially expanding the drug’s reach across the PBC indication.
In late May 2026, Gilead Sciences reported new Phase 3 post hoc data showing that Livdelzi produced high, durable reductions in key liver markers for people wi…
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new r…
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to…
FOSTER CITY, Calif., June 02, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary c…
Not investment advice. Past performance does not guarantee future results. Full disclaimer